Related Experiment Video
Updated: Jul 1, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer]
Chang Qi1, Panwen Tian1,2, Weimin Li1,3,4
1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.
Neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) shows promise for resectable non-small cell lung cancer (NSCLC). This review explores recent advancements, benefits, and challenges of neoadjuvant immunotherapy in NSCLC treatment.
Area of Science:
- Oncology
- Immunology
- Thoracic Surgery
Background:
- Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC).
- Immunotherapy demonstrates significant value in resectable NSCLC, but neoadjuvant strategies require further investigation.
- Controversies exist regarding combination strategies, side effects, and biomarkers in the neoadjuvant setting for NSCLC.
Conclusions:
- Neoadjuvant immunotherapy represents a significant advancement in the treatment of resectable NSCLC.
- Further research is needed to optimize combination strategies, manage side effects, and identify predictive biomarkers.
- This review highlights the potential and challenges of neoadjuvant immunotherapy, offering insights for clinical practice.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...